About

Gubra is a biotech company delivering pre-clinical contract research services within
obesity and diabetes. Gubra is an abbreviation for gut and brain, the key focus
areas of our research and expertise. We combine cutting-edge technology
with our accumulated experience and proven methodology in order to
challenge the existing assumptions regarding the treatment of diabetes
and obesity.

1 Gubra is a biotech company delivering pre-clinical contract research services within obesity and diabetes.
2 Gubra is an abbreviation for gut and brain, the key focus areas of our research and expertise.
3 We combine cutting-edge technology with our accumulated experience and proven methodology in order to challenge the existing assumptions regarding the treatment of diabetes and obesity.
4 Bring us a problem, and we find the solution together. We work with you to identify the best approach, to determine the right protocols and to select the appropriate models. Collaboration is the key to the Gubra approach.
5 Our methods emphasize precision and accuracy.
6 We combine cutting-edge technology with our accumulated experience and proven methodology in order to challenge the existing assumptions regarding the treatment of diabetes
and obesity.

Why we do it

We want to unravel the pathophysiology of diabetes and obesity so as to better treat these diseases. It is the science that drives us.

How we do it

Within the areas of diabetes and obesity, we design
experiments that will answer your questions. We believe in
simplicity, in designing an experiment in such a way that you get clear, usable data and answers to the questions relevant to your compound and study.

Together we can discuss the right approach for your study. We are always ready for a non-confidential or confidential discussion of your project/idea.

Contact us


About the management

Henrik Blou

Henrik Blou (CEO) holds a Master’s of Science in Chemical Engineering. He has spent the past 10 years as a serial biotech entrepreneur in MycoTeQ A/S (co-founder, CEO), Aros Pharma ApS (CEO) and EpiTherapeutics ApS (BD/Corp. Dev. Director; sold to Gilead Sciences Inc. in May 2015) and as consultant for other biotech startups. Henrik has extensive experience with deals and negotiations, business development and managing preclinical and early clinical companies. He started his career as a management consultant with McKinsey & Co.

Phone: +45 2861 6845 · E-mail: hbl@gubra.dk

Keld Fosgerau

Keld Fosgerau (CSO) holds a Master’s of Science in Biological Chemistry and an industrial PhD in hepatic glycogen metabolism. The past 16+ years he has been deeply involved in metabolic research, most of the time focusing on diabetes and obesity. Keld has been covering the full spectrum from large pharma corporation to small biotech start-up and has a long history of scientific leadership, alliance management and people management. Functionally his focus has primarily been on target biology, pharmacology and drug discovery. Keld has published more than 75 articles and communications on metabolic research.

Phone: +45 2980 6369 · E-mail: kfo@gubra.dk

Henrik Blou

Jan K. Villadsen (CFO) has been working more than 35 years in the financial sector as well as in private and public companies before joining Gubra. Most recently he was the SVP of Debt Capital Markets at Nykredit. Prior to this position he was the CFO of two biotech companies, NatImmune A/S and Neurokey A/S. Other previous positions include Head of Financial Solutions (Nykredit); Group Treasurer (Group 4 Falck A/S); Head of Treasury (KommuneKredit); First Vice President, Debt Capital Markets (Baltica Bank); Vice President, Debt Capital Markets (Hafnia Merchant Bank).

Phone: +45 2067 0709 · E-mail: jkv@gubra.dk

Helle Kirstein Erichsen

Helle Kirstein Erichsen (COO) holds a Master's of Science and a PhD in behavioural pharmacology. Helle has a strong carrier as a people manager working 12 years in danish biotech within drug discovery with special focus at neurology. She has been actively involved in exploring new drug targets, characterizing candidates in early discovery and pre-clinical programs, in addition to developing/validating in vivo behavioural pharmacology models.

Phone: +45 5191 1846 · E-mail: hke@gubra.dk

Niels Vrang

Niels Vrang (Co-founder, Chairman of the Board) holds an MD and a PhD in in vivo pharmacology investigating effects of peptides on appetite regulation. He has spent the past 20 years actively engaged in basic and applied research focusing on circadian rhythms, food intake, body weight and diabetes. Niels was co-founder of Rheoscience and director of discovery from 2002-2008. He has published more than 80 research papers.

Phone: +45 3152 2651 · Email: niels@gubra.dk

Jacob Jelsing

Jacob Jelsing (Co-founder, board member) holds a Master’s of Science and a PhD in stereology. He has spent the past 10 years actively engaged in research, with a primary expertise in the development of stereological research methods and anatomical changes related to type II diabetes, obesity and neurodegenerative disorders. Jacob has worked intensively with beta cell dynamics in different animal models and the characterization of endocrine cell populations in animal models of gastric bypass surgery. Jacob has published more than 40 full research papers covering these topics.

Phone: +45 3152 2652 · E-mail: jacob@gubra.dk

Tino Klein

Tino Klein (Head of Facility and Technologies) holds a master of science in protein chemistry and a PhD in pancreas regeneration. He has a 15 years background in diabetes research at Novo Nordisk preferentially working with pancreas development and histology, in vitro/ in vivo stem cell differentiation, generation of transgenic animals and drug discovery. In addition, he successfully established and ran a transgenic mouse core unit. Tino is experienced in line mgmt and project coordination. He has published several papers within his research.

E-mail: tk@gubra.dk

Janne Skarsø Erwolter

Janne Skarsø Erwolter (Senior HR Partner) holds a Graduate Diploma in Business Administration, Organization & Management and has extensive, broad-based experience within the HR disciplines. Janne has worked several years as a Management Consultant and Manager within Recruitment and Management Development. Prior to joining Gubra, Janne worked for more than 4 years as HR Manager in an engineering company.

E-mail: jse@gubra.dk


Gubra was co-founded in 2008 by Drs. Niels Vrang, Jacob Jelsing and Mads Tang Christensen (now Vice President at Novo Nordisk).

Gubra appoints Chief Operating Officer

April 6, 2017 — Today, Helle Kirstein Erichsen has been appointed COO of Gubra. In this newly created position Helle Kirstein Erichsen will focus on optimizing processes, logistics and resource utilization across the organization as well as ensure smooth daily operations.

Read the press release here

Gubra appoints new CSO

November 1, 2016 — Today, Gubra announced a change in its executive management team by appointing Keld Fosgerau as new Chief Science Officer (CSO).

Read the press release here

Gubra and Clinical-Microbiomics Announces Pre-clinical Microbiome Partnership

August 29, 2016 — Two renowned research companies – one focused on preclinical research and discovery, the other on tailored microbiomic analysis – team up in order to help uncover the microbiomic components of diabetes, obesity and NAFLD/NASH.

Read the press release here

Gubra announces new executive management team

June 1, 2016 — On the back of record growth across all parameters, Gubra is pleased to announce a new management team who will help continue the track record of growth and focus on scientific research and discovery.

Read the press release here

Gubra Appoints Henrik Blou as Chief Business Officer

November 23, 2015 — Gubra ApS, a preclinical metabolic drug discovery company has appointed Henrik Blou as Chief Business Officer of Gubra. At the same time Gubra has acquired a 3500 m2 combined research and office facility in Hørsholm in order to accommodate the needs of Gubra’s rapidly growing business.

Read the press release here

Gubra ApS Announces Metabolism Focused ‘Discover & Translate’ Partnership with Profil Institute

June 6, 2015 — Two renowned metabolic clinical research companies – one focused on preclinical research and discovery, the other on translational clinical research – join forces to validate novel compounds for diabetes, obesity and NAFLD/NASH.

Read the press release here

Gubra reaches second research milestone in collaboration agreement with Sanofi

March 25, 2015 — We are pleased to announce that we have reached our second milestone in our collaboration with Sanofi focusing on the discovery of new peptides suitable for development of peptide based drugs for treatment of people with diabetes and obesity.

Read the press release here

Gubra reaches first research milestone in Sanofi collaboration

October 23, 2014 — We are proud to announce that a collaborative research effort over the past year involving virtually all Gubra employees has made it possible to reach the first research milestone (on time!) in our target discovery collaboration with Sanofi.

Read the press release here

Gubra announces research collaboration agreement with Sanofi

September 23, 2013 — This new research collaboration will focus on discovering and developing peptide-based drugs for use in treating diabetes and obesity. Read more about this new project in the press release.

Read the press release here

Scientists with a

business perspective

We know our results ultimately have to generate value for your company. That’s why we focus on the quality and completeness of the data we provide. We choose the methodology that will yield the most usable results for your company. Scientific research requires care, accuracy and precision. This is the delicate balance we walk. Pursuing methods with scientific merit to give you results that you can use, and that will ultimately generate value for your business.